GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (OSTO:MODTX) » Definitions » Inventories, Finished Goods

Modus Therapeutics Holding AB (OSTO:MODTX) Inventories, Finished Goods : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Modus Therapeutics Holding AB Inventories, Finished Goods?


Modus Therapeutics Holding AB Inventories, Finished Goods Historical Data

The historical data trend for Modus Therapeutics Holding AB's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modus Therapeutics Holding AB Inventories, Finished Goods Chart

Modus Therapeutics Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial - - - - -

Modus Therapeutics Holding AB Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Modus Therapeutics Holding AB Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Modus Therapeutics Holding AB Business Description

Traded in Other Exchanges
Address
Olof Palmes gata 29 IV, Stockholm, SWE, 111 22
Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney diseases through its patented polysaccharide sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.

Modus Therapeutics Holding AB Headlines

No Headlines